NR4A1 and neoplasm: Patients with hormone receptor‐negative tumors were less likely to experience TTC delays compared with hormone receptor‐positive patients, it is possible that there was likely a greater sense of urgency among providers to initiate chemotherapy in patients with these tumor types given their more aggressive behavior.